403
Sorry!!
Error! We're sorry, but the page you were
looking for doesn't exist.
Roche purchases cell treatment company Poseida Therapeutics
(MENAFN) Roche, which is a Swiss medicine company, declared on Tuesday that it will buy cell treatment maker company Poseida Therapeutics for an overall transaction worth USD1.5 billion.
The transaction is going to facilitate a variety of possibly "first and best-in-class therapies" through oncology, immunology, as well as neurology, uniquely ranking Roche in the new division of donor-derived off-the-shelf cell treatments, Roche said in a media release.
The operation is projected to accomplish in the Q1 of the upcoming year.
The transaction will be done for USD9 per share, and stakeholders will also get a non-tradeable contingent worth nearly USD4 per share, marking an overall agreement worth some USD1.5 billion.
Poseida is a public clinical-stage biopharmaceutical company in donor-derived CAR-T cell treatments, originated in California, United States.
Poseida’s research and improvement portfolio involves pre-clinical as well as clinical-stage off-the-shelf, chimeric antigen receptor T (CAR-T) treatments all over various therapeutic fields, such as hematological malignancies, hard tumors, and autoimmune disease, and manufacturing capabilities and technology platforms.
The transaction is going to facilitate a variety of possibly "first and best-in-class therapies" through oncology, immunology, as well as neurology, uniquely ranking Roche in the new division of donor-derived off-the-shelf cell treatments, Roche said in a media release.
The operation is projected to accomplish in the Q1 of the upcoming year.
The transaction will be done for USD9 per share, and stakeholders will also get a non-tradeable contingent worth nearly USD4 per share, marking an overall agreement worth some USD1.5 billion.
Poseida is a public clinical-stage biopharmaceutical company in donor-derived CAR-T cell treatments, originated in California, United States.
Poseida’s research and improvement portfolio involves pre-clinical as well as clinical-stage off-the-shelf, chimeric antigen receptor T (CAR-T) treatments all over various therapeutic fields, such as hematological malignancies, hard tumors, and autoimmune disease, and manufacturing capabilities and technology platforms.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Most popular stories
More Story
Comments
No comment